Westfield Capital Management Co. LP Takes Position in Abivax SA Sponsored ADR $ABVX

Westfield Capital Management Co. LP purchased a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the fourth quarter, HoldingsChannel reports. The institutional investor purchased 1,009,966 shares of the company’s stock, valued at approximately $136,199,000.

A number of other hedge funds also recently made changes to their positions in the stock. TD Asset Management Inc boosted its stake in shares of Abivax by 37.5% in the 4th quarter. TD Asset Management Inc now owns 63,902 shares of the company’s stock valued at $8,618,000 after purchasing an additional 17,416 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Abivax by 94.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 263,533 shares of the company’s stock valued at $35,539,000 after purchasing an additional 127,907 shares in the last quarter. AdvisorShares Investments LLC acquired a new stake in shares of Abivax in the 4th quarter valued at approximately $1,510,000. Geode Capital Management LLC boosted its stake in shares of Abivax by 67.3% in the 4th quarter. Geode Capital Management LLC now owns 49,933 shares of the company’s stock valued at $6,734,000 after purchasing an additional 20,081 shares in the last quarter. Finally, Clearstead Advisors LLC acquired a new stake in shares of Abivax in the 4th quarter valued at approximately $138,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax Price Performance

Shares of NASDAQ ABVX opened at $104.93 on Friday. The company has a 50 day simple moving average of $117.00 and a 200 day simple moving average of $119.83. The firm has a market cap of $8.36 billion, a PE ratio of -20.14 and a beta of 0.69. Abivax SA Sponsored ADR has a 1 year low of $5.69 and a 1 year high of $148.83.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The business had revenue of $1.56 million during the quarter, compared to the consensus estimate of $0.40 million. As a group, research analysts anticipate that Abivax SA Sponsored ADR will post -3.18 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Citizens Jmp raised their price target on shares of Abivax from $131.00 to $187.00 and gave the company a “market outperform” rating in a research note on Tuesday. Citigroup reiterated an “outperform” rating on shares of Abivax in a report on Tuesday. Oddo Bhf reiterated an “outperform” rating on shares of Abivax in a report on Thursday, April 9th. Truist Financial dropped their price objective on shares of Abivax from $140.00 to $135.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Jefferies Financial Group lowered shares of Abivax from a “buy” rating to a “hold” rating and dropped their price objective for the company from $160.00 to $90.00 in a report on Tuesday. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $130.08.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.